Max Petersson
Geschäftsführer bei Accuro Immunology AB
Aktive Positionen von Max Petersson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Accuro Immunology AB
 Accuro Immunology AB Pharmaceuticals: MajorHealth Technology Accuro Immunology AB develops and manufactures active immunotherapy products. The firm's products help to treat the patients suffering from problems with immune escape/evasion. The company was founded by Peter Gunnar Maurits Wolpert and Elisabeth Wolpert in 1999 and is headquartered in Stockholm, Sweden. | Geschäftsführer | - | - |
Karriereverlauf von Max Petersson
Ehemalige bekannte Positionen von Max Petersson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
AngioGenetics AB
 AngioGenetics AB Pharmaceuticals: GenericHealth Technology AngioGenetics AB develops, markets, and distributes generic drugs. It develops angiogenesis modulating drugs for the treatment of cancer, ischemic heart disease, and eye diseases. The company was founded in June 2001 and is headquartered in Göteborg, Sweden. | Corporate Officer/Principal | - | - |
Ausbildung von Max Petersson
| Karolinska Institutet | Doctorate Degree |
Statistik
International
| Schweden | 4 |
Operativ
| Chief Operating Officer | 1 |
| Doctorate Degree | 1 |
| Corporate Officer/Principal | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Accuro Immunology AB
Accuro Immunology AB Pharmaceuticals: MajorHealth Technology Accuro Immunology AB develops and manufactures active immunotherapy products. The firm's products help to treat the patients suffering from problems with immune escape/evasion. The company was founded by Peter Gunnar Maurits Wolpert and Elisabeth Wolpert in 1999 and is headquartered in Stockholm, Sweden. | Health Technology |
AngioGenetics AB
AngioGenetics AB Pharmaceuticals: GenericHealth Technology AngioGenetics AB develops, markets, and distributes generic drugs. It develops angiogenesis modulating drugs for the treatment of cancer, ischemic heart disease, and eye diseases. The company was founded in June 2001 and is headquartered in Göteborg, Sweden. | Health Technology |
- Börse
- Insiders
- Max Petersson
- Erfahrung
